[Toward a treatment for dementia].
The clinical manifestations of so-called 'untreatable dementias' result from neuronal dysfunction causing premature neuronal death. As long as the neurosciences won't have an explanation for the increased vulnerability and cause of death of neurons in neurodegenerative disorders, no preventive or curative treatment can be expected. So far, the treatment of dementia focuses essentially on the consequences of neuronal dysfunction or cell loss by either a palliative approach addressing psychosis, behavior or anxiety and depression, or by substitution of deficient neurotransmitters with quasi no success. Only tacrine, a cholinesterase inhibitor, now available in Switzerland, has a marginal effect in early cases, but every other substitutive approach has failed so far. Muscarinic agonists as well as antiamyloid substances will be tested soon in clinical trials. Growth factors (especially NGF) raise big hopes for the near future, but they are still under preclinical evaluation.
D000368:Aged; D000544:Alzheimer Disease / Q000628:therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003704:Dementia / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000627:therapeutic use; D010166:Palliative Care; D013619:Tacrine / Q000627:therapeutic use
D002800:Cholinesterase Inhibitors; D009414:Nerve Growth Factors; D013619:Tacrine
Vers un traitement des démences.